These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Dual Wood AC; Krytska K; Ryles HT; Infarinato NR; Sano R; Hansel TD; Hart LS; King FJ; Smith TR; Ainscow E; Grandinetti KB; Tuntland T; Kim S; Caponigro G; He YQ; Krupa S; Li N; Harris JL; Mossé YP Clin Cancer Res; 2017 Jun; 23(11):2856-2868. PubMed ID: 27986745 [No Abstract] [Full Text] [Related]
24. A novel pyrrole-imidazole polyamide targets Aurora kinase A and suppresses tumor growth in vivo. Li M; Lu D; Cheng Y; Wu C; Zhang J; Shi W; Ding Z; Li Y; Cheng B; Lin X; Shao X; Li H; Fang L; Liu K; Su W Biochem Biophys Res Commun; 2021 Sep; 571():167-173. PubMed ID: 34330060 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of alkylating pyrrole-imidazole polyamide conjugates by a novel method for high-throughput sequencer. Kashiwazaki G; Maeda R; Kawase T; Hashiya K; Bando T; Sugiyama H Bioorg Med Chem; 2018 Jan; 26(1):1-7. PubMed ID: 29224995 [TBL] [Abstract][Full Text] [Related]
26. Identification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation. Mishra R; Watanabe T; Kimura MT; Koshikawa N; Ikeda M; Uekusa S; Kawashima H; Wang X; Igarashi J; Choudhury D; Grandori C; Kemp CJ; Ohira M; Verma NK; Kobayashi Y; Takeuchi J; Koshinaga T; Nemoto N; Fukuda N; Soma M; Kusafuka T; Fujiwara K; Nagase H Cancer Sci; 2015 Apr; 106(4):421-9. PubMed ID: 25611295 [TBL] [Abstract][Full Text] [Related]
28. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. Trigg RM; Lee LC; Prokoph N; Jahangiri L; Reynolds CP; Amos Burke GA; Probst NA; Han M; Matthews JD; Lim HK; Manners E; Martinez S; Pastor J; Blanco-Aparicio C; Merkel O; de Los Fayos Alonso IG; Kodajova P; Tangermann S; Högler S; Luo J; Kenner L; Turner SD Nat Commun; 2019 Nov; 10(1):5428. PubMed ID: 31780656 [TBL] [Abstract][Full Text] [Related]
29. ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation. Borenäs M; Umapathy G; Lai WY; Lind DE; Witek B; Guan J; Mendoza-Garcia P; Masudi T; Claeys A; Chuang TP; El Wakil A; Arefin B; Fransson S; Koster J; Johansson M; Gaarder J; Van den Eynden J; Hallberg B; Palmer RH EMBO J; 2021 Feb; 40(3):e105784. PubMed ID: 33411331 [TBL] [Abstract][Full Text] [Related]
30. Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death. Torossian A; Broin N; Frentzel J; Daugrois C; Gandarillas S; Saati TA; Lamant L; Brousset P; Giuriato S; Espinos E Haematologica; 2019 Jul; 104(7):1428-1439. PubMed ID: 30679328 [TBL] [Abstract][Full Text] [Related]
31. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Bergaggio E; Tai WT; Aroldi A; Mecca C; Landoni E; Nüesch M; Mota I; Metovic J; Molinaro L; Ma L; Alvarado D; Ambrogio C; Voena C; Blasco RB; Li T; Klein D; Irvine DJ; Papotti M; Savoldo B; Dotti G; Chiarle R Cancer Cell; 2023 Dec; 41(12):2100-2116.e10. PubMed ID: 38039964 [TBL] [Abstract][Full Text] [Related]
32. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. Chand D; Yamazaki Y; Ruuth K; Schönherr C; Martinsson T; Kogner P; Attiyeh EF; Maris J; Morozova O; Marra MA; Ohira M; Nakagawara A; Sandström PE; Palmer RH; Hallberg B Dis Model Mech; 2013 Mar; 6(2):373-82. PubMed ID: 23104988 [TBL] [Abstract][Full Text] [Related]
33. Targeting specific gene by alkylating pyrrole-imidazole polyamides. Minoshima M; Chou J; Lefebvre S; Bando T; Shinohara K; Gottesfeld JM; Sugiyama H Nucleic Acids Symp Ser (Oxf); 2008; (52):363-4. PubMed ID: 18776404 [TBL] [Abstract][Full Text] [Related]
34. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas. Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034 [TBL] [Abstract][Full Text] [Related]
35. SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma. Valencia-Sama I; Kee L; Christopher G; Ohh M; Layeghifard M; Shlien A; Hayes MN; Irwin MS Cancer Res Commun; 2023 Dec; 3(12):2608-2622. PubMed ID: 38032104 [TBL] [Abstract][Full Text] [Related]
36. A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells. Cesi G; Philippidou D; Kozar I; Kim YJ; Bernardin F; Van Niel G; Wienecke-Baldacchino A; Felten P; Letellier E; Dengler S; Nashan D; Haan C; Kreis S Mol Cancer; 2018 Oct; 17(1):145. PubMed ID: 30290811 [TBL] [Abstract][Full Text] [Related]
37. The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness. Mus LM; Lambertz I; Claeys S; Kumps C; Van Loocke W; Van Neste C; Umapathy G; Vaapil M; Bartenhagen C; Laureys G; De Wever O; Bexell D; Fischer M; Hallberg B; Schulte J; De Wilde B; Durinck K; Denecker G; De Preter K; Speleman F Sci Rep; 2020 Jan; 10(1):218. PubMed ID: 31937834 [TBL] [Abstract][Full Text] [Related]
38. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling. Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976 [TBL] [Abstract][Full Text] [Related]